DIMENSION THERAPEUTICS INC (DMTX) Stock Price & Overview
NASDAQ:DMTX • US25433V1052
Current stock price
The current stock price of DMTX is 5.95 null. Today DMTX is down by -0.42%. In the past month the price decreased by -0.83%. In the past year, price increased by 3.48%.
DMTX Key Statistics
- Market Cap
- 150M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.23
- Dividend Yield
- N/A
DMTX Stock Performance
DMTX Stock Chart
DMTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to DMTX. When comparing the yearly performance of all stocks, DMTX is one of the better performing stocks in the market, outperforming 99.2% of all stocks.
DMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMTX. DMTX may be in some trouble as it scores bad on both profitability and health.
DMTX Earnings
DMTX Forecast & Estimates
DMTX Financial Highlights
Over the last trailing twelve months DMTX reported a non-GAAP Earnings per Share(EPS) of -2.2305. The EPS decreased by -364.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -336% | ||
| ROA | -111.28% | ||
| ROE | -274.1% | ||
| Debt/Equity | 0.14 |
DMTX Ownership
About DMTX
Company Profile
Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.
Company Info
DIMENSION THERAPEUTICS INC
840 Memorial Drive
CAMBRIDGE MA 02139
CEO: Annalisa Jenkins
Phone: 617-401-0011
DIMENSION THERAPEUTICS INC / DMTX FAQ
What does DMTX do?
Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.
What is the current price of DMTX stock?
The current stock price of DMTX is 5.95 null. The price decreased by -0.42% in the last trading session.
Does DIMENSION THERAPEUTICS INC pay dividends?
DMTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of DMTX stock?
DMTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.